RESUMO
There is an unmet need for effective treatments of Clostridioides difficile infection, an emerging health crisis in the United States. The management of C. difficile infection should include treatment of active infection and a strategy to prevent recurrence. Current gold standard therapy includes oral antibiotics which predispose patients to gut dysbiosis and increase the risk of recurrent infection. Addressing dysbiosis via fecal microbiota transplantation is an active and promising area of research, but studies have lacked standardization which makes outcome and safety data difficult to interpret. Rebyota™, formerly known as RBX2660, is a live biotherapeutic product designed using a standardized protocol and manufacturing process that has been shown to be effective for preventing recurrent C. difficile infection.
Clostridioides difficile infection is becoming more common in the USA and causes profuse diarrhea that can be deadly. Treatment with antibiotics causes dysregulation of the bacteria in the gut putting patients at a higher risk of reinfection. Fecal microbiota live jslm is a new therapy approved by the US FDA that uses stool from healthy donors to return gut bacteria levels to normal after treatment for a C. diff infection.